By Mill Chart
Last update: May 2, 2024
Growth investors are looking for stocks showing high revenue and EPS growth. We will have a look here to see if ALKERMES PLC (NASDAQ:ALKS) is suited for growth investing. Investors should of course do their own research, but we spotted ALKERMES PLC showing up in our Louis Navellier growth screen, so it may be worth spending some more time on it.
Every day, ChartMill assigns a Fundamental Rating to each stock, providing a score ranging from 0 to 10. This rating is determined by evaluating various fundamental indicators and properties.
Taking everything into account, ALKS scores 6 out of 10 in our fundamental rating. ALKS was compared to 588 industry peers in the Biotechnology industry. ALKS has an excellent financial health rating, but there are some minor concerns on its profitability. A decent growth rate in combination with a cheap valuation! Better keep an eye on ALKS. These ratings could make ALKS a good candidate for value investing.
Our latest full fundamental report of ALKS contains the most current fundamental analsysis.
More ideas for growth investing can be found on ChartMill in our Lois Navellier screen.
Important Note: The content of this article is not intended as trading advice. It is essential to perform your own analysis and exercise caution when making trading decisions. The article presents observations created by automated analysis but does not guarantee any trading or investment outcomes. Always trade responsibly and make independent judgments.
ALKERMES PLC
NASDAQ:ALKS (5/9/2024, 8:33:05 AM)
24.27
+0.17 (+0.71%)
ALKERMES PLC (NASDAQ:ALKS) is probably undervalued for the fundamentals it is displaying.
/PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) has completed the previously announced sale of its development and manufacturing facility in Athlone, Ireland to...
Should you consider ALKERMES PLC (NASDAQ:ALKS) for growth investing?
ALKS stock results show that Alkermes missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024.
/PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced initiation of the Vibrance-1 study, a phase 2 clinical trial evaluating the safety and efficacy of...
/PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m. BST) on Wednesday, May 1, 2024 to...
/PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced the oral presentation of clinical data at the 2024 Congress of the Schizophrenia International...